INSM Stock Analysis: Buy, Sell, or Hold?
INSM - Insmed, Inc.
$125.77
0.69 (0.55%)
â˛
5d:
+1.64%
30d:
+17.09%
90d:
+14.83%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When INSM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: INSM is fairly priced but lacks strong directional signals. At -14.1% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: INSM is fairly priced but lacks strong directional signals. At -14.1% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$25.22
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$15.66
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: INSM is currently trading at $125.77, which is considered slightly high relative to its 30-day fair value range of $101.80 to $126.86. From a valuation perspective, the stock is trading at a discount (Forward PE: 174.7) compared to its historical average (275.5). Remarkably, the market is currently pricing in an annual earnings decline of 14.1% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, INSM is in a downtrend. The price is currently testing key support at $122.21. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: INSM scores 26/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $200.05 (+59.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, INSM is in a downtrend. The price is currently testing key support at $122.21. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: INSM scores 26/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $200.05 (+59.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$101.80 -
$126.86
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
42.9%
Protect Your Profits
Holding INSM? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Weak technical setup (26/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 59.1% below Wall St target ($200.05)
- WARNING: Composite score 40/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$101.80 -
$126.86
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$122.21
Resistance Level
$135.50
Current Trend
Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
174.70
Wall Street Target
$200.05
(+59.1%)
Revenue Growth (YoY)
296.1%
Profit Margin
-76.9%
Valuation Discount vs History
-14.1% cheaper
PE vs Historical
174.7 vs 275.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-14.1%
(market-implied from PE analysis)
1-Year Target
$113.19
(-10%)
2-Year Target
$101.87
(-19%)
3-Year Target
$91.69
(-27%)
3-Yr Target (if PE normalizes)
(PE: 175â276)
$144.58
(+15%)
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 174.7 to 275.5
Stabilization Target:
$198.33
(+57.7%)
PE Expansion Potential:
+57.7%
Share & Embed Analysis
Last updated: August 23, 2026 12:21 AM ET
Data refreshes hourly during market hours. Next update: 1:21 AM
Data refreshes hourly during market hours. Next update: 1:21 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INSM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
William Lewis
SELL
10699 shares
2026-04-16
William Lewis
SELL
10699 shares
2026-04-06
Roger Adsett
SELL
88060 shares
2026-04-01
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 57 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
RCKT
Rocket Pharmaceuticals IâĻ |
STRONG BUY
18 analysts |
$9 | 53 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$89 | 40 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$309 | 51 HOLD |
Advanced INSM Option Strategies
Professional options setups generated by AI based on today's INSM price and gamma walls.
